Gain of function mutations in p53
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
We report that the expression of murine or human mutant p53 proteins in cells with no endogenous p53 proteins confers new or additional phenotypes upon these cells. Mutant p53 proteins expressed in cell lines lacking p53 resulted in either enhanced tumorigenic potential in nude mice ((10)3 cells) or enhanced plating efficiency in agar cell culture (human SAOS-2 cells). Also, mutant human p53 alleles, unlike the wild-type p53 protein, could also enhance the expression of a test gene regulated by the multi-drug resistance enhancer-promoter element. These data demonstrate a gain of function associated with p53 mutations in addition to the loss of function shown previously to be associated with mutations in this tumour suppressor gene.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GOF mut-p53 is associated with enhanced proliferation, migration, invasion and resistance to chemotherapy [59,68,69].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [59]
In the citing paper
“Importantly, mut-p53 protein is highly expressed in GBM and numerous studies have demonstrated that mut-p53 possesses oncogenic functions beyond those acquired through wt-p53 loss.”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [59]
In the citing paper
“Multiple studies, using either cellular models expressing specific p53 variants or mouse models, suggest an oncogenic GOF for specific p53 variants via the activation of specific pathways associated with metastasis, metabolic reprogramming, or cell differentiation [53].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [52]
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Self-citationThe p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Self-citationMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citationAssociation of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Self-citationChromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Self-citationDefinition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Research works printed but not linked: 2
- Hinds, P.W. et al. Mutant p53 cDNAs from human colorectal carcinomas can cooperate with ras in transformation of primary rat cells: A comparison of the “hot spot” mutant phenotypes. Cell Growth Diff. 1, 571–580 (1990).
- Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K.U. & Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912–915 (1990). · DOI · Paper page
Cited by
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Self-citationMuller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Unravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Clinical Implications of the p53 Tumor-Suppressor Gene
Harris, C. C., & Hollstein, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,330
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
“This notion, termed the 'gain-of-function hypothesis', received its first support when transfection of mutant p53 into TP53 -null cells was shown to enhance their ability to form tumours in mic”
BackgroundGain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Mutant p53 Gain-of-Function in Cancer
Oren, M., & Rotter, V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753
Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J. R., & Harris, C. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2230 · Cited by 665
Twenty years of p53 research: structural and functional aspects of the p53 protein
May, P., & May, E. (1999) · Oncogene · doi:10.1038/sj.onc.1203285 · Cited by 663
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
The RNA-Editing Enzyme ADAR1 Controls Innate Immune Responses to RNA
Mannion, N. M., Greenwood, S. M., Young, R., Cox, S., Brindle, J., Read, D., Nellåker, C., Vesely, C., Ponting, C. P., McLaughlin, P. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.041 · Cited by 656
Role of p53 in Cell Death and Human Cancers
Ozaki, T., & Nakagawara, A. (2011) · Cancers · doi:10.3390/cancers3010994 · Cited by 650
Why are there hotspot mutations in the TP53 gene in human cancers?
Baugh, E. H., Ke, H., Levine, A. J., Bonneau, R. A., & Chan, C. S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.180 · Cited by 607
Self-citationp53 signaling in cancer progression and therapy
Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., Morrione, A., Giordano, A., & Cenciarelli, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02396-8 · Cited by 588
p53 modulation of TFIIH–associated nucleotide excision repair activity
Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J.-M., Wang, Z., Friedberg, E. C., Evans, M. K., Taffe, B. G., et al. (1995) · Nature Genetics · doi:10.1038/ng0695-188 · Cited by 554
The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer
Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M., & Jacks, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2193 · Cited by 553
Crystal Structure of the Tetramerization Domain of the p53 Tumor Suppressor at 1.7 Angstroms
Jeffrey, P. D., Gorina, S., & Pavletich, N. P. (1995) · Science · doi:10.1126/science.7878469 · Cited by 549
Mutations and altered expression of p16INK4 in human cancer.
Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., & Beach, D. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11045 · Cited by 539
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marin, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O'Nions, J., Tidy, J. A., James, N., McGregor, J. M., Harwood, C. A., Yulug, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 515
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
p63 and p73: Roles in Development and Tumor Formation
Moll, U. M., & Slade, N. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.371.2.7 · Cited by 486
P53, cell cycle control and apoptosis: Implications for cancer
Kastan, M. B., Canman, C. E., & Leonard, C. J. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690207 · Cited by 482
p53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 481
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
p53 Research: The Past Thirty Years and the Next Thirty Years
Lane, D., & Levine, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000893 · Cited by 454
Self-citationA dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., et al. (2019) · Science · doi:10.1126/science.aax3649 · Cited by 441
“Supporting evidence comes from in vitro and in vivo studies in mice that have demonstrated higher oncogenic potential of p53 missense tumors as compared to p53 null tumors (9, 10).”
Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 441
Self-citationAn Attempt to Prevent Senescence: A Mitochondrial Approach
Skulachev, V. P., Anisimov, V. N., Antonenko, Y. N., Bakeeva, L. E., Chernyak, B. V., Erichev, V. P., Filenko, O. F., Kalinina, N. I., Kapelko, V. I., Kolosova, N. G., et al. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.12.008 · Cited by 430
The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis
Levine, A., Perry, M., Chang, A., Silver, A., Dittmer, D., Wu, M., & Welsh, D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.76 · Cited by 422
Self-citationDi Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418
“specific DNA binding consensus is still unknown, and consequently modulate sets of genes that mediate its protumorigenic activities (Dittmer et al., 1993; Blandino et al., 1999).”
BackgroundInfluentialA comparison of the biological activities of wild‐type and mutant p53
Zambetti, G. P., & Levine, A. J. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344485 · Cited by 413
Self-citationGain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Sanada, M., Suzuki, T., Shih, L.-Y., Otsu, M., Kato, M., Yamazaki, S., Tamura, A., Honda, H., Sakata-Yanagimoto, M., Kumano, K., et al. (2009) · Nature · doi:10.1038/nature08240 · Cited by 402
The role of mutant p53 in human cancer
Goh, A. M., Coffill, C. R., & Lane, D. P. (2011) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 398
Transcriptional regulation of ABC drug transporters
Scotto, K. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206950 · Cited by 392
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
Kadosh, E., Snir-Alkalay, I., Venkatachalam, A., May, S., Lasry, A., Elyada, E., Zinger, A., Shaham, M., Vaalani, G., Mernberger, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2541-0 · Cited by 378
Niemeyer, C. M., Kang, M. W., Shin, D. H., Furlan, I., Erlacher, M., Bunin, N. J., Bunda, S., Finklestein, J. Z., Sakamoto, K. M., Gorr, T. A., et al. (2010) · Nature Genetics · doi:10.1038/ng.641 · Cited by 374
van Bokhoven, H., Hamel, B. C. J., Bamshad, M., Sangiorgi, E., Gurrieri, F., Duijf, P. H. G., Vanmolkot, K. R. J., van Beusekom, E., van Beersum, S. E. C., Celli, J., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/323123 · Cited by 373
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a loss
Terzian, T., Suh, Y.-A., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Van Pelt, C. S., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 357
Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations
Bardeesy, N., Falkoff, D., Petruzzi, M.-J., Nowak, N., Zabel, B., Adam, M., Aguiar, M. C., Grundy, P., Shows, T., & Pelletier, J. (1994) · Nature Genetics · doi:10.1038/ng0594-91 · Cited by 339
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
Willis, A., Jung, E. J., Wakefield, T., & Chen, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207396 · Cited by 330
Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6360 · Cited by 320
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
Self-citationMutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Blagosklonny, M. V., Toretsky, J., Bohen, S., & Neckers, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8379 · Cited by 314
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.
Wang, X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H., et al. (1996) · Genes & Development · doi:10.1101/gad.10.10.1219 · Cited by 313
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308
Soussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
Targeting p53 as a general tumor antigen.
Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., & Sherman, L. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.11993 · Cited by 304
Self-citationVenot, C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4668 · Cited by 292
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Del Sal, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 289
Huang, S., Endo, R. I., & Nemerow, G. R. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2257-2263.1995 · Cited by 289
Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells.
Lowe, S. W., Jacks, T., Housman, D. E., & Ruley, H. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2026 · Cited by 287
Harris, C. C. (1996) · Carcinogenesis · doi:10.1093/carcin/17.6.1187 · Cited by 285
Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic Pathway
Woods, C. M., Zhu, J., McQueney, P. A., Bollag, D., & Lazarides, E. (1995) · Molecular Medicine · doi:10.1007/bf03401588 · Cited by 282
Tumor Suppressor p53 Protein Is a New Target for the Metastasis-associated Mts1/S100A4 Protein
Grigorian, M., Andresen, S., Tulchinsky, E., Kriajevska, M., Carlberg, C., Kruse, C., Cohn, M., Ambartsumian, N., Christensen, A., Selivanova, G., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010231200 · Cited by 282
p53 mutation heterogeneity in cancer
Soussi, T., & Lozano, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.190 · Cited by 275
Mutant p53: an oncogenic transcription factor
Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 269
Rosen, E. M., Fan, S., Pestell, R. G., & Goldberg, I. D. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10257 · Cited by 268
Bargonetti, J., Manfredi, J. J., Chen, X., Marshak, D. R., & Prives, C. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2565 · Cited by 265
Courtois, S., Verhaegh, G., North, S., Luciani, M.-G., Lassus, P., Hibner, U., Oren, M., & Hainaut, P. (2002) · Oncogene · doi:10.1038/sj.onc.1205874 · Cited by 263
Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes
Theobald, M., Biggs, J., Hernández, J., Lustgarten, J., Labadie, C., & Sherman, L. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.5.833 · Cited by 256
Majumder, M., Ghosh, A. K., Steele, R., Ray, R., & Ray, R. B. (2001) · Journal of Virology · doi:10.1128/jvi.75.3.1401-1407.2001 · Cited by 255
MDR- and CYP3A4-mediated drug–herbal interactions
Pal, D., & Mitra, A. K. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.010 · Cited by 254
Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1
Sampath, J., Sun, D., Kidd, V. J., Grenet, J., Gandhi, A., Shapiro, L. H., Wang, Q., Zambetti, G. P., & Schuetz, J. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103429200 · Cited by 244
Self-citationAmbs, S., Hussain, S. P., & Harris, C. C. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.6.9194524 · Cited by 233
Hui, L., Zheng, Y., Yan, Y., Bargonetti, J., & Foster, D. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209735 · Cited by 218
“…in human cancer are very rare (Blagosklonny, 2000). p53 mutants have been shown to confer tumorigenic properties to cells lacking wild-type p53 (Dittmer et al., 1993; Hsiao et al., 1994; Lanyi et al., 1998; Scian et al., 2004), indicating that the ability of p53 genes to contribute to cell…”
BackgroundMartinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222406899 · Cited by 210
Mutant p53: it’s not all one and the same
Kennedy, M. C., & Lowe, S. W. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00989-y · Cited by 198
Young, K. H., Leroy, K., Møller, M. B., Colleoni, G. W. B., Sánchez-Beato, M., Kerbauy, F. R., Haioun, C., Eickhoff, J. C., Young, A. H., Gaulard, P., et al. (2008) · Blood · doi:10.1182/blood-2008-01-129783 · Cited by 191
Metallothionein 2A expression is associated with cell proliferation in breast cancer
Jin, R. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.81 · Cited by 186
Léveillard, T., Andera, L., Bissonnette, N., Schaeffer, L., Bracco, L., Egly, J. M., & Wasylyk, B. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00506.x · Cited by 173
The many faces of p53: something for everyone
Levine, A. J. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz026 · Cited by 163
Self-citationBrown, D. R., Thomas, C. A., & Palit Deb, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.9.2513 · Cited by 148
The UMD TP53 database and website: update and revisions
Hamroun, D., Kato, S., Ishioka, C., Claustres, M., Béroud, C., & Soussi, T. (2006) · Human Mutation · doi:10.1002/humu.20269 · Cited by 140
Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123
“Of note, mutant p53 has been shown to have oncogenic properties in cells which are p53 null, ruling out the simple possibility of a dominant-negative effect over endogenous wt p53 (Dittmer et al., 1993; Wang et al., 1998; Liu et al., 2000).”
BackgroundWild-Type Human p53 Transactivates the Human Proliferating Cell Nuclear Antigen Promoter
Shivakumar, C. V., Brown, D. R., Deb, S., & Deb, S. P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6785 · Cited by 120
“p53 mutants activate promoters of genes expressing human proliferating cell nuclear antigen (PCNA), human epidermal growth factor receptor (EGFR), multiple drug resistance (MDR1), and human HSP70 in vivo (9, 13, 14, 16, 75, 84).”
BackgroundAggarwal, M., Saxena, R., Sinclair, E., Fu, Y., Jacobs, A., Dyba, M., Wang, X., Cruz, I., Berry, D., Kallakury, B., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.48 · Cited by 101
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations
Li, Y., Guessous, F., Kwon, S., Kumar, M., Ibidapo, O., Fuller, L., Johnson, E., Lal, B., Hussaini, I., Bao, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1963 · Cited by 95
Alam, S. K., Yadav, V. K., Bajaj, S., Datta, A., Dutta, S. K., Bhattacharyya, M., Bhattacharya, S., Debnath, S., Roy, S., Boardman, L. A., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.133 · Cited by 91
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
“…protein conferred several new properties upon the cells: more rapid cell division, higher plating efficiency on plastic cell surfaces and in agar suspension, and greater efficiency of making tumors in animals, all of which were definitions of the transformed phenotype (Dittmer et al. 1993).”
BackgroundSelf-citationMenendez, D., Inga, A., & Resnick, M. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2297-2308.2006 · Cited by 81
Degtjarik, O., Golovenko, D., Diskin-Posner, Y., Abrahmsén, L., Rozenberg, H., & Shakked, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-27142-6 · Cited by 78
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79
Junk, D. J., Vrba, L., Watts, G. S., Oshiro, M. M., Martinez, J. D., & Futscher, B. W. (2008) · Neoplasia · doi:10.1593/neo.08120 · Cited by 74
Wei, W., Jobling, W. A., Chen, W., Hahn, W. C., & Sedivy, J. M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.8.2859-2870.2003 · Cited by 68
“form primary human cells on their own (10, 11, 17, 81).”
BackgroundPRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68
Zhao, M., Wang, T., Gleber-Netto, F. O., Chen, Z., McGrail, D. J., Gomez, J. A., Ju, W., Gadhikar, M. A., Ma, W., Shen, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44239-2 · Cited by 65
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014) · Apoptosis · doi:10.1007/s10495-014-0990-3 · Cited by 59
The TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 50
Krex, D., Mohr, B., Appelt, H., Schackert, H. K., & Schackert, G. (2003) · Neurosurgery · doi:10.1227/01.neu.0000093426.29236.86 · Cited by 42
Characterization of p53 Family Homologs in Evolutionary Remote Branches of Holozoa
Bartas, M., Brázda, V., Červeň, J., & Pečinka, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010006 · Cited by 29
Metadata
- Authors
- Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J.
- Affiliations
- Princeton University (US)
- Venue
- Nature Genetics
- Published
- 1993-05
- Volume
- 4
- Issue
- 1
- Pages
- 42-46
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2043912950
- Cited by
- 894
- References
- 40
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 18 · 2023: 26 · 2022: 25 · 2021: 26 · 2020: 27 · 2019: 30 · 2018: 19 · 2017: 20 · 2016: 28 · 2015: 20 · 2014: 31 · 2013: 14 · 2012: 16
- FWCI
- 18.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca055036-03)
- National Cancer Institute (P01CA041086, R01 CA55036)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, gain-of-function mutations, tumor suppressor, tumorigenicity, plating efficiency, transcriptional activation, Saos-2 cells
- MeSH terms
- Animals, Carrier Proteins, Cell Division, Cell Line, Clone Cells, Gene Expression Regulation, Humans, Membrane Glycoproteins, Mice, Inbred BALB C, Mice, Nude, Mutation, Neoplasms, Experimental, Phenotype, Species Specificity, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, ATP Binding Cassette Transporter, Subfamily B, Member 1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.